SCHEMBL8384792

SCHEMBL8384792

CC(=O)OC1CCC(c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 6/20 0.55
AKR1C3 P42330 1/20 0.47
AKR1C1 Q04828 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NPY5R Q15761 1/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
FABP7 O15540 1/20 0.42
FABP5 Q01469 1/20 0.42
HCRTR2 O43614 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
KCNH2 Q12809 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8730453 0.95 SLC18A3 (0.51) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL8730449 0.95 SLC18A3 (0.51) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL28372457 0.94 SLC18A3 (0.53) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL21826495 0.85 AKR1C3 (0.50) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL21826434 0.85 AKR1C3 (0.50) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL21826494 0.85 AKR1C3 (0.50) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL21826435 0.85 AKR1C3 (0.50) SLC18A3AKR1C3AKR1C1NPC1RAB9A
SCHEMBL4558845 0.84 ESR2 (0.55)
SCHEMBL5246202 0.84 ESR2 (0.55)
SCHEMBL10660930 0.83 SLC18A3 (0.44) SLC18A3AKR1C3AKR1C1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021188620-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA INC. (US) 2021-09-23 WO disclosed
CN-103288721-B (4-(4-[6-(trifluoromethylpyridin-3-base amino)-containing N heteroaryl]-phenyl)-cyclohexyl)-acetogenin and pharmaceutical use thereof NOVARTIS AG (CH) 2016-04-20 CN disclosed
CN-103288721-A (4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof NOVARTIS AG 2013-09-11 CN disclosed
CN-101415683-B Novel compounds NOVARTIS AG 2013-07-17 CN disclosed
CN-103086981-A New compounds NOVARTIS AG 2013-05-08 CN disclosed
CN-101415683-A Novel compounds NOVARTIS AG (CH) 2009-04-22 CN disclosed
US-5962507-A BLOCKING CHOLESTEROL BIOSYNTHESIS DR. KARL THOMAE GMBH (DE) 1999-10-05 US disclosed
EP-0757669-B1 O-ACYL-4-PHENYL-CYCLOHEXANOLS, THEIR SALTS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE, AS WELL AS A METHOD OF PREPARING THEM BOEHRINGER INGELHEIM PHARMA (DE) 1998-11-18 EP disclosed
US-5726205-A ANTICHOLESTEROL AGENTS KARL THOMAE GMBH (DE) 1998-03-10 US disclosed
EP-0757669-A1 O-ACYL-4-PHENYL-CYCLOHEXANOLS, THEIR SALTS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE, AS WELL AS A METHOD OF PREPARING THEM Dr. Karl Thomae GmbH (DE) 1997-02-12 EP disclosed
WO-1995029148-A1 O-ACYL-4-PHENYL-CYCLOHEXANOLS, THEIR SALTS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE, AS WELL AS A METHOD OF PREPARING THEM DR. KARL THOMAE GMBH (DE) 1995-11-02 WO disclosed